All In Biotech

Drug Trial Radar · NCT01478607

A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients

A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy

Last checked: Nov 20, 2026Latest source record: Oct 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

468

Actual

Start

Nov 2011

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Nov 23, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety of repeated applications of QUTENZA in reducing pain intensity in subjects who have peripheral neuropathic pain due to diabetes.

Conditions

  • Painful Diabetic Peripheral Neuropathy (PDPN)

Interventions

  • QUTENZADrug

    A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scaleTime frame: Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks)

Locations

64 sites in 11 countries. Site status is shown where the registry gives one.

  • Site: 601

    Bonheiden, Belgium

  • Site: 903

    Beroun, Czechia

  • Site: 910

    Brno, Czechia

  • Site: 908

    Choceň, Czechia

  • Site: 911

    Litoměřice, Czechia

  • Site: 906

    Ostrava, Czechia

  • Site: 904

    Polička, Czechia

  • Site: 901

    Prague, Czechia

  • Site: 902

    Přerov, Czechia

  • Site: 909

    Rychnov nad Kněžnou, Czechia

  • Site: 207

    Bron, France

  • Site: 202

    Paris, France

  • Site: 201

    Pierre-Bénite, France

  • Site: 206

    Toulouse, France

  • Site: 508

    Chiemsee, Germany

  • Site: 509

    Cologne, Germany

  • Site: 502

    Dresden, Germany

  • Site: 501

    Falkensee, Germany

  • Site: 514

    Frankfurt, Germany

  • Site: 507

    Hamburg, Germany

  • Site: 505

    Leipzig, Germany

  • Site: 506

    Münster, Germany

  • Site: 512

    Wangen, Germany

  • Site: 404

    Milan, Italy

  • Site: 401

    Roma, Italy

  • Site: 651

    Utrecht, Netherlands

  • Site: 965

    Bialystok, Poland

  • Site: 961

    Bydgoszcz, Poland

  • Site: 957

    Elblag, Poland

  • Site: 958

    Gdynia, Poland

  • Site: 954

    Katowice, Poland

  • Site: 964

    Krakow, Poland

  • Site: 951

    Lodz, Poland

  • Site: 966

    Lubin, Poland

  • Site: 953

    Poznan, Poland

  • Site: 959

    Torun, Poland

  • Site: 960

    Warsaw, Poland

  • Site: 714

    Kemerovo, Russia

  • Site: 703

    Saint Petersburg, Russia

  • Site: 716

    Saint Petersburg, Russia

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.